Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Costa

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Breast Care (Basel, Switzerland)|November 5, 2010
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)Matthias W Beckmann, Jens-Uwe Blohmer, Serban-Dan Costa, et al.
Breast Cancer Research and Treatment|November 3, 2010
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trialsGunter von Minckwitz, Michael Untch, Eveline Nüesch, et al.
Annals of Surgical Oncology|July 28, 2019
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized TrialsDavid Krug, Bianca Lederer, Fenja Seither, et al.
The Lancet. Oncology|February 13, 2016
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trialMichael Untch, Christian Jackisch, Andreas Schneeweiss, et al.
Breast Care (Basel, Switzerland)|November 12, 2015
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German ExpertsChristian Jackisch, Nadia Harbeck, Jens Huober, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto StudyPeter A Fasching, Sibylle Loibl, Chunling Hu, et al.
Breast Care (Basel, Switzerland)|January 14, 2014
13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013)Michael Untch, Bernd Gerber, Nadia Harbeck, et al.
International Journal of Cancer|June 24, 2015
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto studyAlexander Hein, Diether Lambrechts, Gunter von Minckwitz, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Breast Care (Basel, Switzerland)|November 5, 2010
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)Matthias W Beckmann, Jens-Uwe Blohmer, Serban-Dan Costa, et al.
Breast Cancer Research and Treatment|November 3, 2010
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trialsGunter von Minckwitz, Michael Untch, Eveline Nüesch, et al.
Annals of Surgical Oncology|July 28, 2019
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized TrialsDavid Krug, Bianca Lederer, Fenja Seither, et al.
The Lancet. Oncology|February 13, 2016
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trialMichael Untch, Christian Jackisch, Andreas Schneeweiss, et al.
Breast Care (Basel, Switzerland)|November 12, 2015
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German ExpertsChristian Jackisch, Nadia Harbeck, Jens Huober, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto StudyPeter A Fasching, Sibylle Loibl, Chunling Hu, et al.
Breast Care (Basel, Switzerland)|January 14, 2014
13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013)Michael Untch, Bernd Gerber, Nadia Harbeck, et al.
International Journal of Cancer|June 24, 2015
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto studyAlexander Hein, Diether Lambrechts, Gunter von Minckwitz, et al.
Pageof 10